Market Report, "Refractory Multiple Myeloma - Pipeline Review, H2 2013", Published
Global Markets Direct's, 'Refractory Multiple Myeloma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Refractory Multiple Myeloma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma. Refractory Multiple Myeloma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites,...
View full press release